151 related articles for article (PubMed ID: 31405664)
1. The implication of hepatokines in metabolic syndrome.
Esfahani M; Baranchi M; Goodarzi MT
Diabetes Metab Syndr; 2019; 13(4):2477-2480. PubMed ID: 31405664
[TBL] [Abstract][Full Text] [Related]
2. Hepatokines and non-alcoholic fatty liver disease.
Lebensztejn DM; Flisiak-Jackiewicz M; Białokoz-Kalinowska I; Bobrus-Chociej A; Kowalska I
Acta Biochim Pol; 2016; 63(3):459-67. PubMed ID: 27262842
[TBL] [Abstract][Full Text] [Related]
3. Implication of hepatokines in metabolic disorders and cardiovascular diseases.
Jung TW; Yoo HJ; Choi KM
BBA Clin; 2016 Jun; 5():108-13. PubMed ID: 27051596
[TBL] [Abstract][Full Text] [Related]
4. Acute Hyperenergetic, High-Fat Feeding Increases Circulating FGF21, LECT2, and Fetuin-A in Healthy Men.
Willis SA; Sargeant JA; Yates T; Takamura T; Takayama H; Gupta V; Brittain E; Crawford J; Parry SA; Thackray AE; Varela-Mato V; Stensel DJ; Woods RM; Hulston CJ; Aithal GP; King JA
J Nutr; 2020 May; 150(5):1076-1085. PubMed ID: 31919514
[TBL] [Abstract][Full Text] [Related]
5. Inflammation Markers in Type 2 Diabetes and the Metabolic Syndrome in the Pediatric Population.
Reinehr T; Roth CL
Curr Diab Rep; 2018 Oct; 18(12):131. PubMed ID: 30338401
[TBL] [Abstract][Full Text] [Related]
6. Hepatokines: unlocking the multi-organ network in metabolic diseases.
Iroz A; Couty JP; Postic C
Diabetologia; 2015 Aug; 58(8):1699-703. PubMed ID: 26032022
[TBL] [Abstract][Full Text] [Related]
7. Identification of hepatokines involved in pathology of type 2 diabetes and obesity.
Misu H
Endocr J; 2019 Aug; 66(8):659-662. PubMed ID: 31366824
[TBL] [Abstract][Full Text] [Related]
8. Role of exercise-induced hepatokines in metabolic disorders.
Ennequin G; Sirvent P; Whitham M
Am J Physiol Endocrinol Metab; 2019 Jul; 317(1):E11-E24. PubMed ID: 30964704
[TBL] [Abstract][Full Text] [Related]
9. A New Insight into the Roles of MiRNAs in Metabolic Syndrome.
Huang Y; Yan Y; Xv W; Qian G; Li C; Zou H; Li Y
Biomed Res Int; 2018; 2018():7372636. PubMed ID: 30648107
[TBL] [Abstract][Full Text] [Related]
10. Effects of Exercise Intervention on Mitochondrial Stress Biomarkers in Metabolic Syndrome Patients: A Randomized Controlled Trial.
Chang JS; Namkung J
Int J Environ Res Public Health; 2021 Feb; 18(5):. PubMed ID: 33668309
[TBL] [Abstract][Full Text] [Related]
11. Interaction between hepatokines and metabolic diseases.
Liang JQ; Liu C; Zhang WX; Chen SY
Yi Chuan; 2022 Oct; 44(10):853-866. PubMed ID: 36384723
[TBL] [Abstract][Full Text] [Related]
12. The Role of Lipids in the Pathogenesis of Metabolic Syndrome in Adolescents.
Taghizadeh S; Alizadeh M
Exp Clin Endocrinol Diabetes; 2018 Jan; 126(1):14-22. PubMed ID: 29117624
[TBL] [Abstract][Full Text] [Related]
13. Hepatokines as a Link between Obesity and Cardiovascular Diseases.
Yoo HJ; Choi KM
Diabetes Metab J; 2015 Feb; 39(1):10-5. PubMed ID: 25729707
[TBL] [Abstract][Full Text] [Related]
14. Circulating Concentrations of Insulin Resistance-Associated Hepatokines, Selenoprotein P and Leukocyte Cell-Derived Chemotaxin 2, during an Oral Glucose Tolerance Test in Humans.
Mohri K; Misu H; Takayama H; Ishii KA; Kikuchi A; Lan F; Enyama Y; Takeshita Y; Saito Y; Kaneko S; Takamura T
Biol Pharm Bull; 2019 Mar; 42(3):373-378. PubMed ID: 30606895
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory Biomarkers and Components of Metabolic Syndrome in Adolescents: a Systematic Review.
de F Rocha AR; de S Morais N; Priore SE; do C C Franceschini S
Inflammation; 2022 Feb; 45(1):14-30. PubMed ID: 34546513
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Syndrome as a Multifaceted Risk Factor for Oxidative Stress.
Spahis S; Borys JM; Levy E
Antioxid Redox Signal; 2017 Mar; 26(9):445-461. PubMed ID: 27302002
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021.
Fahed G; Aoun L; Bou Zerdan M; Allam S; Bou Zerdan M; Bouferraa Y; Assi HI
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054972
[TBL] [Abstract][Full Text] [Related]
18. Hepatokines as a Molecular Transducer of Exercise.
Seo DY; Park SH; Marquez J; Kwak HB; Kim TN; Bae JH; Koh JH; Han J
J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33498410
[TBL] [Abstract][Full Text] [Related]
19. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance.
Meex RCR; Watt MJ
Nat Rev Endocrinol; 2017 Sep; 13(9):509-520. PubMed ID: 28621339
[TBL] [Abstract][Full Text] [Related]
20. Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism.
Kim TH; Hong DG; Yang YM
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
